"Insulin, Long-Acting" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Insulin formulations that contain substances that retard absorption thus extending the time period of action.
| Descriptor ID |
D049528
|
| MeSH Number(s) |
D06.472.699.587.200.300 D12.644.548.586.200.300
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Insulin, Long-Acting".
Below are MeSH descriptors whose meaning is more specific than "Insulin, Long-Acting".
This graph shows the total number of publications written about "Insulin, Long-Acting" by people in this website by year, and whether "Insulin, Long-Acting" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 4 | 0 | 4 |
| 2015 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Insulin, Long-Acting" by people in Profiles.
-
Second-generation basal insulins to initiate insulin therapy in type 2 diabetes: A need for clinical evidence before incurring increased costs. Diabetes Obes Metab. 2020 05; 22(5):719-721.
-
EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETES. Endocr Pract. 2019 Feb; 25(2):144-155.
-
Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial. JAMA. 2017 Jul 04; 318(1):45-56.
-
PATIENTS ACHIEVING GOOD GLYCEMIC CONTROL (HBA1c <7%) EXPERIENCE A LOWER RATE OF HYPOGLYCEMIA WITH INSULIN DEGLUDEC THAN WITH INSULIN GLARGINE: A META-ANALYSIS OF PHASE 3A TRIALS. Endocr Pract. 2015 Aug; 21(8):917-26.
-
Lessons from glargine trials: what is the goal fasting glucose with basal insulin? J Diabetes. 2014 Jul; 6(4):271-3.
-
Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized begin trials. Endocr Pract. 2014 Apr; 20(4):285-92.
-
Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2-year trial in insulin-na?ve patients with type 2 diabetes. Diabetes Obes Metab. 2014 Sep; 16(9):869-72.
-
A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). Diabetes Obes Metab. 2014 Jul; 16(7):636-44.
-
Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type?2 diabetes: a 2-year randomized, treat-to-target trial. Diabet Med. 2013 Nov; 30(11):1298-304.
-
Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012 Dec; 35(12):2464-71.